Cure My Disease

Don't miss your cure!

 Log in / Sign up

Early safety check for potential sepsis clot treatment begins in japan

NCT ID NCT07176728

Recruiting now Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 27 times

Summary

This early-stage study tests a new drug, BAY 3389934, in 16 healthy Japanese adults to see if it is safe and how the body handles it. The drug is being developed for a serious blood clotting problem that can happen with severe infections. Participants receive either the drug or a placebo by IV, and researchers monitor side effects and measure drug levels in the blood. Results will help plan future studies in patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPSIS ASSOCIATED DISSEMINATED INTRAVASCULAR COAGULATION (DIC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • SOUSEIKAI Fukuoka Mirai Hospital

    RECRUITING

    Fukuoka, Fukuoka Pref, 813-0017, Japan

    Contact

  • SOUSEIKAI Fukuoka Mirai Hospital

    RECRUITING

    Fukuoka, 813-0017, Japan

Conditions

Explore the condition pages connected to this study.

SEPSIS ASSOCIATED DISSEMINATED INTRAVASCULAR COAGULATION (DIC)